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Quantitative faecal immunochemical tests for haemoglobin (FIT) are increasingly 
being used in the UK and elsewhere to assist in the assessment of patients 
presenting to primary care with lower bowel symptoms to guide referral for further 
investigation, often colonoscopy.  A very low or undetectable faecal haemoglobin 
concentration (f-Hb) has been demonstrated in multiple studies to have a very high 
negative predictive value for colorectal cancer (CRC).1.  In 2017, the National 
Institute for Health and Care Excellence (NICE) issued Diagnostics Guidance DG30 
which encouraged the use of FIT in the assessment of patients at low risk of CRC.2  
These guidelines were then incorporated into the NICE guidance NG12 on referral of 
patients considered at risk of CRC.3  DG30 advises that patients with symptoms 
considered low risk for CRC and with f-Hb < 10ug Hb/ g do not need to be referred 
on the NHS England two week wait pathway and can instead be monitored in 
primary care.  
There are an  ever-growing number of publications demonstrating the value of FIT as 
a rule-out investigation for CRC, in high-risk as well as low-risk symptomatic 
patients. particularly as a rule-out test for CRC.4   The reason for this significant 
interest was that the rapidly evolving evidence was that FIT provides a simple and 
inexpensive test that might stem some of the ever increasing demands on scarce 
endoscopy services, which do not actually lead to significantly more CRC being 
detected.5 
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Then, the COVID-19 pandemic arrived, which led to almost complete cessation of 
endoscopy.   This stimulated much discussion about how the many patients already 
referred for investigation of symptoms, and the new patients presenting with 
symptoms, could be provided with the best care in the challenging circumstances. 
Recent NHS England and NHS Improvement guidance stated: 6 Clinicians may 
prioritise referrals using patient-reported symptoms together with blood test results 
(including full blood count (FBC) and  FIT. The accompanying clinical guidance 
stated that patients should therefore be prioritised for further investigation according 
to a triage process, not documented here in detail, which involved FIT.  The 
guidance from the Scottish Government is similar and states that, when colonoscopy 
is either severely restricted or not available, a numerical f-Hb result and a FBC 
should be available whenever possible before a patient is considered for 
investigation of large bowel symptoms.7 Both English and Scottish guidances have 
higher thresholds (f-Hb >100 μg Hb/g faeces in England; f-Hb >400 μg Hb/g faeces 
in Scotland) whereby patients require urgent investigations.
In both sets of guidance, patients with a f-Hb <10 µg Hb/g faeces are considered 
very low risk for CRC.  In England, the guidance states these patients with NG12 
symptoms and f-Hb <10 μg Hb/g faeces should be safety-netted to a patient tracking 
list and, in Scotland, those with a f-Hb <10 μg Hb/g faeces should only be offered 
investigation where there is significant on-going clinical concern.   
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The guidance from England states that appropriate safety-netting should be put in 
place for patients who do not require immediate investigation, to allow for a further 
clinical assessment should their symptoms worsen.  The Scottish guidance has 
details on use of FIT: if a patient has a FIT result <10 μg Hb/g faeces, but has 
persistent symptoms, a primary care review within six weeks is recommended and, if 
there is still doubt as to whether or not to refer, a repeat FIT may be of value. 
Further, in the Scottish guidance. it is documented that, in the recovery phase of 
COVID-19, repeating FIT in patients on the waiting list may help prioritisation.
It is well documented that FIT are not the perfect diagnostic test and, although FIT 
are far better than symptoms alone in the detection of CRC,8 some cases of CRC do 
have f-Hb <10 μg Hb/g faeces.  In consequence, for such patients, especially if their 
symptoms continue, safety-netting is ubiquitously recommended.  Safety-netting 
strategies are designed so that people at low risk, but not at no risk, of having CRC 
are actively monitored in primary care to see if th  risk of CRC changes.9  
Interestingly, as per the Scottish guidelines,  recent reviews,4,10 a “best practice” 
guidelines paper commissioned by the Royal College of Pathologists,11 and a recent 
paper,12 all  propose that repeat FIT might be of value, if symptoms persist, as a 
component of safety-netting approaches. 
However, the current problem is that there is no objective evidence to support or 
refute the use of  repeat FIT in  patients with f-Hb <10 µg Hb/g faeces, who are 
probably at very low risk of CRC and other significant bowel diseases.  Several 
asymptomatic population-based CRC screening programmes use two or three faecal 
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specimens, but these are taken from consecutive bowel motions with a view to 
enhancing sensitivity for the detection of CRC: lowering the f-Hb threshold achieves 
the same laudable aim.  Some FIT-based post polypectomy screening programmes 
use two samples, for example, that conducted in South Australia.13 There are only 
three studies, to our knowledge, that examine multiple specimen collection in the 
clinical setting of assessment of patients with symptoms: two have used quantitative 
FIT on sequential bowel motions14,15 and one has used a qualitative FIT and three 
specimens.16  However, again these replicate specimens have been collected to 
investigate whether sensitivity for CRC detection can be enhanced by using more 
than one specimen, not repeat specimens for the safety-netting of patients with f-Hb 
<10 µg Hb/g faeces.  
There is an urgent need for research into several crucial aspects of the application of 
repeat FIT in patients presenting with symptoms and with f-Hb  <10 µg Hb/g faeces.  
Necessary prerequisites to the optimum care of this large group of patients include 
generation of objective evidence on :
 should recommendations be developed regarding the most appropriate time 
interval that should elapse before a second FIT is requested: should this 
depend on symptom severity, 
 should more than one repeat FIT be done if symptoms persist beyond the 
finding of two low f-Hb,
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 if the repeat result is f-Hb >10 µg Hb/g faeces, should this be the criterion for 
referral for further investigation, or should a further repeat FIT be performed 
for confirmation of an increase in f-Hb,
 should  a threshold of <10 µg Hb/g faeces be applied as the criterion for 
reassurance, watching and waiting, or further safety-netting, since available 
FIT analytical systems have detectability characteristics17 that are below this f-
Hb,18 allowing f-Hb to be detected at very low f-Hb and quantitated at lower f-
Hb than this threshold: lower thresholds do increase diagnostic sensitivity for 
CRC, although positivity and colonoscopy demands do increase,19
 should repeat or serial estimates of f-Hb in specimens from an individual 
patient be performed on one type of FIT system, since different systems give 
different numerical f-Hb results, especially at low f-Hb,18 and
 should professional bodies provide further best practice guidelines on how the 
sources of pre-analytical, analytical and post-analytical variation can be 
minimised to ensure that any changes seen in an individual are due to  
important physiological or pathophysiological deterioration.
We urge all those involved in application of FIT in assessment of patients with 
symptoms, especially those with f-Hb <10 µg Hb/g faeces, to undertake pure or 
applied research, and/or report their findings to date, on repeat FIT, so that evidence 
can be gathered, lessons learned and best practice identified and ubiquitously 
translated into routine practice.
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